Clinical trials: Baseline/Control Phase
New-onset Type 1 Diabetes
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
The objective of this clinical trial was to assess whether ladarixin treatment is effective to improve glycemic control in newly diagnosed Type 1 Diabetes (T1D) adult patients with preserved β-cell function.
- Trial name
- NCT04899271
- Testing
- Ladarixin
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Dompé Farmaceutici S.p.A
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH
Neurogenic Detrusor Overactivity
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence).
- Trial name
- NCT05621616
- Testing
- mirabegron
- Where
- 3 sites in Philippines, Poland
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in…
- Trial name
- NCT02028884
- Testing
- Satralizumab, Baseline Treatment
- Where
- 40 sites in United States, France and 9 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Non-Insulin-Dependent Diabetes Mellitus
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.
- Trial name
- NCT00359112
- Testing
- metformin, sulphonylurea, Avandamet
- Where
- 142 sites in Belgium, France and 9 more
- Volunteers
- 544 people
- Sponsor
- GlaxoSmithKline
Recent Onset type1 Diabetes
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients.
- Trial name
- NCT04628481
- Testing
- Ladarixin
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 289 people
- Sponsor
- Dompé Farmaceutici S.p.A
Hepatocellular Carcinoma
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein.
- Trial name
- REACH-2 (NCT02435433)
- Testing
- Ramucirumab
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Microcystic Lymphatic Malformation
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess…
- Trial name
- SELVA (NCT06239480)
- Testing
- QTORIN 3.9% Rapamycin Anhydrous Gel
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- Palvella Therapeutics, Inc.
Coronary Artery Disease, Dyslipidemia
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
This study is designed to provide an assessment of the change in baseline lipid parameters with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized statin background therapy in subjects with low…
- Trial name
- SUSTAIN (NCT01423188)
- Testing
- RVX000222
- Where
- 25 sites in South Africa
- Volunteers
- 176 people
- Sponsor
- Resverlogix Corp
Coccidioidomycosis, Disseminated Fungal Infection
A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care
The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated…
- Conditions
- Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection, Coccidioides Immitis Infection
- Trial name
- COCCIMETRICS (NCT07712484)
- Testing
- Olorofim
- Volunteers
- 50 people
- Sponsor
- F2G Ltd
Cutaneous Venous Malformations
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
- Trial name
- TOIVA (NCT06653842)
- Testing
- QTORIN 3.9% rapamycin anhydrous gel
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- Palvella Therapeutics, Inc.
Fabry Disease, Lysosomal Storage Diseases
A Fabry Disease Gene Therapy Study
This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
- Trial name
- MARVEL1 (NCT04040049)
- Testing
- FLT190
- Where
- 13 sites in United States, Austria and 5 more
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
HIV-1-infection
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus…
- Trial name
- ARTISTRY-1 (NCT05502341)
- Testing
- Bictegravir, Lenacapavir, BIC/LEN FDC
- Where
- 94 sites in United States, Argentina and 13 more
- Volunteers
- 689 people
- Sponsor
- Gilead Sciences
Chronic Constipation, Constipation
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with placebo in patients with chronic constipation (CC) and prominent abdominal bloating.
- Trial name
- NCT01642914
- Testing
- Linaclotide 290 micrograms, Linaclotide 145 micrograms
- Where
- 151 sites in United States, Canada
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment…
- Trial name
- Meteoroid (NCT05271409)
- Testing
- Satralizumab
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Neurogenic Detrusor Overactivity
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
- Trial name
- NCT01565694
- Testing
- Solifenacin succinate
- Where
- 21 sites in United States, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Astellas Pharma Europe B.V.
Neurogenic Detrusor Overactivity, Pediatric
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
- Trial name
- NCT01981954
- Testing
- Solifenacin succinate
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Europe B.V.
Infertility
CONSORT Randomized Controlled Trial in Assisted Reproductive Technology
The overall objective of this trial is to compare the ovarian response in assisted reproductive technology (ART) subjects administered GONAL f® according to the 'Consistency in recombinant follicle stimulating hormone [r-FSH]…
- Trial name
- NCT00829244
- Testing
- GONAL f® prefilled pen
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Angiokeratomas
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
- Trial name
- LOTU (NCT07552077)
- Testing
- PTX-022
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Palvella Therapeutics, Inc.
Sickle Cell Disease
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants.
- Trial name
- RAISE (NCT03997760)
- Testing
- TAK-755
- Where
- 14 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shire